CancerDrs

Breast Cancer clinical trials in Maryland

32 actively recruiting breast cancer trials at 21 sites across Maryland.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full breast cancer transparency page →

Phase 3 Recruiting Network

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Maryland:
  • UM Upper Chesapeake Hematology and Oncology - Aberdeen — Aberdeen, Maryland
  • Luminis Health Anne Arundel Medical Center — Annapolis, Maryland
  • University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
  • UM Upper Chesapeake Medical Center — Bel Air, Maryland
  • UPMC Western Maryland — Cumberland, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…

Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in Maryland:
  • University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
  • Greater Baltimore Medical Center — Baltimore, Maryland
  • Sinai Hospital of Baltimore — Baltimore, Maryland
  • Saint Agnes Hospital — Baltimore, Maryland
  • MedStar Franklin Square Medical Center/Weinberg Cancer Institute — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in Maryland:
  • UM Upper Chesapeake Hematology and Oncology - Aberdeen — Aberdeen, Maryland
  • University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
  • Greater Baltimore Medical Center — Baltimore, Maryland
  • Sinai Hospital of Baltimore — Baltimore, Maryland
  • MedStar Franklin Square Medical Center/Weinberg Cancer Institute — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Maryland:
  • Maryland Proton Treatment Center — Baltimore, Maryland
  • University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
  • Sinai Hospital of Baltimore — Baltimore, Maryland
  • UM Upper Chesapeake Medical Center — Bel Air, Maryland
  • Central Maryland Radiation Oncology in Howard County — Columbia, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…

Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in Maryland:
  • Sinai Hospital of Baltimore, Inc. — Baltimore, Maryland
  • St. Agnes Hospital — Baltimore, Maryland
  • Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
  • American Oncology Partners of Maryland, PA — Bethesda, Maryland
  • James M Stockman Cancer Institute — Frederick, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early b…

Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06492616
Sites in Maryland:
  • Mercy Medical Center — Baltimore, Maryland
  • Ascension St. Agnes Hospital — Baltimore, Maryland
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
  • Maryland Oncology Hematology, P.A. — Columbia, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBC…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05827081
Sites in Maryland:
  • Mercy Medical Center — Baltimore, Maryland
  • Maryland Oncology Hematology P A — Silver Spring, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…

Sponsor: AstraZeneca
NCT ID: NCT06103864
Sites in Maryland:
  • Research Site — Baltimore, Maryland
  • Research Site — Columbia, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribo…

Sponsor: Hoffmann-La Roche
NCT ID: NCT06065748
Sites in Maryland:
  • Maryland Oncology Hematology — Annapolis, Maryland
  • Frederick Health Hospital — Frederick, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in th…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06966700
Sites in Maryland:
  • Mercy Medical Center - Baltimore ( Site 0015) — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…

Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Sites in Maryland:
  • Velocity Clinical Research — Annapolis, Maryland
  • University of Maryland — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…

Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in Maryland:
  • Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have complete…

Sponsor: Greenwich LifeSciences, Inc.
NCT ID: NCT05232916
Sites in Maryland:
  • Maryland Oncology Hematology — Annapolis, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who ha…

Sponsor: LeonaBio
NCT ID: NCT05696626
Sites in Maryland:
  • Johns Hopkins Kimmel Cancer Center — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib and palbociclib plus endocrine therapy for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast …

Sponsor: Celcuity Inc
NCT ID: NCT06757634
Sites in Maryland:
  • American Oncology Partners, P.A. — Bethesda, Maryland
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Maryland:
  • University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
  • Walter Reed National Military Medical Center — Bethesda, Maryland
  • National Institutes of Health Clinical Center — Bethesda, Maryland
  • UPMC Western Maryland — Cumberland, Maryland
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT07102381
Sites in Maryland:
  • Maryland Oncology Hematology — Laurel, Maryland
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

This clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer. The main goals of this study are to: * Learn how well…

Sponsor: SCRI Development Innovations, LLC
NCT ID: NCT05748834
Sites in Maryland:
  • Maryland Oncology Hematology — Columbia, Maryland
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Circulating Tumor DNA

This is a single-arm, phase II study examining elacestrant in the adjuvant treatment of patients with ER+ breast cancer who test positive for circulating tumor DNA (ctDNA) during the screening period of the trial. Our trial will proceed in…

Sponsor: Yale University
NCT ID: NCT06923527
Sites in Maryland:
  • Sidney Kimmel Comprehensive Cancer Center at John Hopkins — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

Eligible patients with stage 2 and 3 triple negative breast cancer will be treated with 4 cycles of neoadjuvant paclitaxel/carboplatin/pembrolizumab. A PET scan will be performed at baseline and after 1 cycle of therapy. A breast MRI will …

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT06245889
Sites in Maryland:
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\[225Ac\]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to e…

Sponsor: Aktis Oncology, Inc.
NCT ID: NCT07020117
Sites in Maryland:
  • United Theranostics — Glen Burnie, Maryland
View on ClinicalTrials.gov →

Showing 25 of 32 trials with sites in Maryland. See all breast cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-17